Drug-diagnostics co-development in oncology

Frontiers in Oncology

Volumn 3 DEC, Issue , 2013, Pages

  Simon, Richard ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adaptive design; Clinical trial design; Companion diagnostic; Enrichment trial; Predictive biomarker

Indexed keywords

DRUG DESIGN; DRUG FORMULATION; DRUG SCREENING; GENETIC HETEROGENEITY; GENOMICS; HUMAN; ONCOLOGY; PATIENT MONITORING; REVIEW; TREATMENT RESPONSE;

EID: 84892409041     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00315     Document Type: Review

References (29)

1. Sawyers CL. The cancer biomarker problem. Nature (2008) 452:548-52. doi: 10.1038/nature06913.
2. Simon RM. Genomic Clinical Trials and Predictive Medicine. Cambridge: Cambridge University Press (2013).
3. Simon R. An agenda for clinical trials: clinical trials in the genomic era. Clin Trials (2004) 1:468-70. doi:10.1191/1740774504cn046xx.
4. Simon R. New challenges for 21st century clinical trials. Clin Trials (2007) 4:167-9. doi:10.1177/1740774507076800.
5. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res (2005) 10:6759-63. doi:10.1158/1078-0432.CCR-04-0496.
6. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials: supplement and correction. Clin Cancer Res (2006) 12:3229. doi:10.1158/1078-0432.CCR-12-10-COR.
7. Maitournam A, Simon R. On the efficiency of targeted clinical trials. Stat Med (2005) 24:329-39. doi:10.1002/sim.1975.
8. Hoering A, LeBlanc M, Crowley J. Randomized phase III clinical trial designs for targeted agents. Clin Cancer Res (2008) 14:4358-67. doi:10.1158/1078-0432.CCR-08-0288.
9. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol (2009) 27:4027-34. doi:10.1200/JCO.2009.22.3701.
10. Simon R, Polley E. Clinical trials for precision oncology using next generation sequencing. Per Med (2013) 10:485-95. doi:10.2217/pme.13.36.
11. Simon R. Using genomics in clinical trial design. Clin Cancer Res (2008) 14:5984-93. doi:10.1158/1078-0432.CCR-07-4531.
12. Freidlin B, Sun Z, Gray R, Korn EL. Phase III clinical trials that integrate treatment and biomarker evaluation. J Clin Oncol (2013) 31:3158-61. doi:10.1200/JCO.2012.48.3826.
13. Simon R, Wang SJ. Use of genomic signatures in therapeutics development. Pharmacogenomcs J (2006) 6:1667-1173. doi:10.1038/sj.tpj.6500349.
14. Wang SJ, O'Neill RT, Hung HM. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm Stat (2007) 6:227-44. doi:10.1002/pst.300.
15. Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst (2010) 102:152-60. doi:10.1093/jnci/djp477.
16. Mandrekar SJ, Sargent DJ. Predictive biomarker validation in practice: lessons from real trials. Clin Trials (2010) 7:567-73. doi:10.1177/1740774510368574.
17. Freidlin B, McShane LM, Polley MY, Korn EL. Randomized phase II trial designs with biomarkers. J Clin Oncol (2012) 28:3304-9. doi:10.1200/JCO.2012.43.3946.
18. Karuri SW, Simon R. A two-stage Bayesian design for co-development of new drugs and companion diagnostics. Stat Med (2012) 31:901-14. doi:10.1002/sim.4462.
19. Jiang W, Freidlin B, Simon R. Biomarker adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Cancer Inst (2007) 99:1036-43. doi:10.1093/jnci/djm022.
20. Simon N, Simon R. Adaptive enrichment designs in clinical trials. Biostatistics (2013) 14:613-25. doi:10.1093/biostatistics/kxt010.
21. Wang SJ, Hung HM, O'Neill RT. Adaptive patient enrichment designs in therapeutic trials. Biom J (2009) 51:358-74. doi:10.1002/bimj.200900003.
22. Follman D. Adaptively changing subgroup proportions in clinical trials. Stat Sin (1997) 7:1085-102.
23. Rosenblum M, Van der Laan MJ. Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment. Biometrika (2011) 98:845-60. doi:10.1093/biomet/asr055.
24. Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res (2005) 11:7872-8. doi:10.1158/1078-0432.CCR-05-0605.
25. Wang SJ, Hung HM, O'Neill RT. Impacts on type I error rate with inappropriate use of learn and confirm in confirmatory adaptive design trials. Biom J (2010) 52:798-810. doi:10.1002/bimj.200900207.
26. Sher HI, Nasso NF, Rubin E, Simon R. Adaptive clinical trials for simultaneous testing of matched diagnostics and therapeutics. Clin Cancer Res (2011) 17:6634-40. doi:10.1158/1078-0432.CCR-11-1105.
27. Matsui S, Simon R, Qu P, Shaughnessy JD, Barlogie B, Crowley J. Developing and validating continuous genomic signatures in randomized clinical trials for predictive medicine. Clin Cancer Res (2012) 18:6065-73. doi:10.1158/1078-0432.CCR-12-1206.
28. Gu X, Yin G, Lee JJ. Bayesian two-step lasso strategy for biomarker selection in personalized medicine development for time to event endpoints. Contemp Clin Trials (2013) 36:642-50. doi:10.1016/j.cct.2013.09.009.
29. Freidlin B, Jiang W, Simon R. The cross-validated adaptive signature design for predictive analysis of clinical trials. Clin Cancer Res (2010) 16:691-8. doi:10.1158/1078-0432.CCR-09-1357.